FDA panel endorses Acambis' smallpox vaccine

The U.K.'s Acambis won the endorsement of an FDA expert panel for its experimental smallpox vaccine. ACAM2000 has been stockpiled in the U.S. over the past six years, but the company needs an FDA approval in order to gain new orders. The vaccine would not be made available to the general public but could be used to vaccinate soldiers who are routinely vaccinated against smallpox. Clinical trials of the vaccine did not result in any deaths, but regulators have been very cautious about the risks posed by ACAM2000. Rare and serious skin infections have been linked to the vaccine.

- here's the MarketWatch report

Related stories:
Acambis restructures as sales rumors circulate Report
Acambis announces new CEO Report
Acambis researching single-shot flu solution Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.